Irregular Red Blood Cell Antibodies Were More Common Than Expected in Tanzanian Donors
A screening study from eastern Tanzania found irregular red blood cell antibodies in 7.6% of eligible blood donors, a prevalence far above the global range commonly cited for donor populations. The finding matters because these antibodies can complicate transfusion compatibility and increase the risk of hemolytic reactions when blood is given to vulnerable recipients, especially patients who require repeated transfusions. In a setting where laboratory resources are limited and blood systems must work close to capacity, even a modest rise in unrecognized antibodies can alter how safely every collected unit is used.
The study evaluated 501 donors at the Eastern Zone Blood Transfusion Center in Dar es Salaam over a two-month period in 2024. The cohort had a mean age of 32 years, and most participants were male. Most also had no prior transfusion history, which makes the prevalence signal more striking rather than less. If irregular antibodies are appearing at this rate in an apparently healthy donor pool, then the transfusion service cannot assume that routine eligibility alone fully protects recipients from immunologic risk.
A single positive screen can change how a unit moves through the blood supply chain.
The Antibody Burden Reached 7.6% in a Mostly Healthy Donor Pool
The overall prevalence of irregular RBC antibodies was 7.6%, with a 95% confidence interval of 5.5% to 10.3%. In transfusion medicine, that figure is not a theoretical concern. Irregular antibodies are not the same as the naturally occurring anti-A and anti-B antibodies that define ABO blood groups; they arise through immune exposure to foreign red cell antigens and can persist long after the triggering event. When those antibodies are present in donated plasma, they may complicate matching or contribute to adverse transfusion outcomes in recipients whose antigen profile is incompatible.
The immune biology here is straightforward even if the operational burden is not. Prior transfusion and pregnancy can stimulate alloimmunization, and once sensitization occurs, the donor’s plasma may contain antibodies against antigens such as those in the Rh, Kell, Kidd, MNS, or Duffy systems. Those antibodies may not harm the donor, but they can matter greatly for the person who receives the blood. This is why donor screening is not merely a laboratory exercise; it is a safety barrier that determines whether a donation is universally usable or only appropriate after more detailed compatibility testing.
Female Sex, Older Age, and Prior Transfusion Carried Higher Odds
Three factors stood out in the analysis. Being female was associated with higher odds of irregular RBC antibodies, with an adjusted odds ratio of 3.4 and a 95% confidence interval of 1.72 to 6.85. Age over 40 years was also associated with higher odds, with an adjusted odds ratio of 4.4 and a 95% confidence interval of 1.29 to 15.00. A history of blood transfusion showed a similar pattern, with an adjusted odds ratio of 3.1 and a 95% confidence interval of 1.53 to 6.42.
Those associations fit the immune mechanism already known in transfusion medicine. Female donors may have had prior antigen exposure through pregnancy, and previous transfusion remains one of the clearest routes to alloantibody formation. Older age may function as a marker of cumulative exposure over time, whether through transfusion, pregnancy, or other sensitizing events that were not directly measured here. The result is not just a statistical pattern; it is a biologically plausible warning that donor history still contains useful signal, even when a person appears clinically well at the donation visit.
In practical terms, the data suggest that donor screening policies in Tanzania may need to take a more explicit account of transfusion history and reproductive exposure. Blood centers often focus on infectious risk and donation eligibility, but immunohematologic risk can be just as consequential for the recipient. When a donor with irregular antibodies contributes to the blood supply, the downstream challenge is not the donation itself. It is the possibility that a unit, once thought to be routine, becomes a source of incompatibility once it reaches a patient with repeated transfusion needs.
Why This Matters for Blood Safety in Resource-Limited Systems
The study was conducted at a major zonal blood center that supplies multiple regions. That setting gives the findings more reach than a single-site laboratory observation. The Eastern Zone Blood Transfusion Center contributes to blood availability across Dar es Salaam, Pwani, Morogoro, and other areas when needed, so the antibody burden described here has implications beyond one collection center. Even without separate data on patient outcomes, the prevalence alone argues for stronger screening practices and more careful use of blood and blood products.
What makes irregular antibodies especially challenging is that they may be clinically silent until a transfusion reaction occurs or compatibility testing reveals a mismatch. In systems where blood is urgently needed and staffing or reagent capacity may be constrained, every additional layer of screening raises operational demands. Yet the alternative is worse: transfusing blood that appears safe on the surface but carries avoidable immunologic risk. The study does not claim that every donor with irregular antibodies would cause harm, but it does show that the risk pool is not negligible.
The findings also reinforce the value of keeping transfusion history visible in donor records. A prior transfusion was a meaningful predictor here, and that should shape how blood services think about pre-donation assessment, laboratory prioritization, and post-donation inventory handling. Female donors and older donors are not exclusion categories by themselves, but the elevated odds in those groups make them important subgroups for antibody awareness and follow-up.
Screening Needs Stronger Support Than Routine Eligibility Checks Alone
The authors concluded that the prevalence was relatively high among eligible donors in Tanzania and called for enhanced screening practices alongside prudent blood use. The study’s own numbers support that position. A prevalence of 7.6% is too substantial to treat as background noise, particularly in a donor population that otherwise appears healthy and mostly free of prior transfusion exposure.
There are limits to what a cross-sectional design can prove, and this study does not establish causation. It also does not map the specific antibody types present, so the exact immunohematologic profile remains undefined in the data provided. Even so, the central message is clear: donor blood can carry hidden antigenic risk, and the burden may be larger than regional practice has assumed. In eastern Tanzania, that should push blood services toward more deliberate antibody screening, better donor history capture, and tighter stewardship of every unit that enters the supply.